Facebook
X
LinkedIn
Forward15th Annual Controversies in Hematologic Malignancies Symposium
This one-day symposium will raise and address the most challenging questions in current clinical practice for hematologic malignancy. Topics will include navigating frontline therapies in Mantle Cell Lymphoma, Multiple Myeloma immunotherapies, Myelodysplastic Syndromes, Relapsed AML, Cardiovascular Complications, and much more.
Target Audience
Physicians, Physician Assistants, Nurse Practitioners, Registered Nurses and Allied Health Professionals
Learning Objectives
Participants who engage in this educational intervention will be able to:
- Evaluate novel agents and various treatments for progression of myelodysplastic syndromes
- Describe current recommendations for immunotherapy in multiple myeloma
- Discuss barriers to and healthcare disparities in the diagnosis and treatment of multiple myeloma.
- Analyze the up-to-date recommendations for frontline management of mantle cell lymphoma
7:30 - 8:25 a.m. View Exhibits/Breakfast
8:25 – 8:30 a.m. Introduction
Lymphoma Block:
8:30 – 8:50 a.m. Primary CNS Lymphoma: Current and Future Treatment Paradigm – Gulrayz Ahmed, MD
8:50 – 9:30 a.m. Frontline Management of MCL in the BTKi era – Jonathon B. Cohen, MD, MS
9:30 – 9:45 a.m. Panel Q&A
9:45 – 10:00 a.m. Break
Leukemia Block:
10:00 – 10:40 a.m. Updates in Relapsed AML - Guru Subramanian Guru Murthy, MD, MS
10:40 – 11:00 a.m. Current State of MDS in 2026 – Amy DeZern, MD
11:00 – 11:15 a.m. Panel Q&A
11:15 – 11:30 a.m. Break
Breakout Sessions:
11:30 a.m. – 12:00 p.m.
Real World Application of Menin Inhibitors in Acute Leukemia – Felicia Zook, PharmD, BCOP
ardiovascular Complications of Hematologic Malignancy - David Lewandowski, MD
Post cellular therapy reporting - Rachel Cusatis, PhD
12:00 p.m. – 12:45 p.m. Lunch
Myeloma Block:
12:45 – 1:05 p.m. Evolving Landscape of AL Amyloid – Sabarinth Radhakrishnan, MD
1:05 – 1:45 p.m. Novel Immunotherapies in Multiple Myeloma – Susan Bal, MD
1:45 – 2:00 p.m. Panel Q&A
2:00 p.m. Adjourn
- Rachel Cusatis, PhD
- Sabarinath Radhakrishnan, MD
| Presenter | Ineligible Companies | Relationship |
|---|---|---|
| David Lewandowski, MD | AstraZeneca | Advisory Committee |
Amy DeZern, MD | Geron, Takeda, Up to Date, AbbVie, AstraZeneca, Beigene, BMS, Kite pharma, Genentech/Roche, Incyte, Janssen, ADC Therapeutics, Galapagos, Ascentage Pharma Genentech/Roche, AstraZeneca, AbbVie, Pepromene, Incyte, BMS | Consultant Research |
Laura Michaelis, MD | Kuros Oncology Merck Pharmaceuticals | Review Board Presenter |
Susan Bal, MD | Bristol Myers Squibb AbbVie, Janssen Biotech | Research Funding Consultant |
Othman Akthar, MD | Sanofi, Janssen Biotech Inmix Biopharma | Advisory Committee Consultant |
Felicia Zook, PharmD, BCOP | Takeda Oncology | Consultant |
| Guru Subramanian Guru Murthy, MD, MS | Cardinal Health, BMS, BeiGene, Pfizer, Gilead/Kite, Astra Zeneca Gilead/Kite, Syndax Gilead/Kite, Amgen, Rigel, Daiichi Sankyo | Speaker, Advisory Board |
Gulrayz Ahmed, MD | Targeted Oncology, Curio Cardinal Health | Consultant Contractor |
Available Credit
- 4.75 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 4.75 Hours of ParticipationHours of Participation credit.